Jim Cramer threw a curveball on Pfizer’s stock during a recent caller interaction, suggesting a wait-and-see approach ...

Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

Bristol Myers Squibb is taking a strategic leap, offloading five immunology assets, including three in clinical stages, to a ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

US pharma major Bristol Myers Squibb revealed it has appointed Dr Cristian Massacesi as executive vice president, chief ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

Bristol Myers Squibb has appointed Dr Cristian Massacesi as Executive Vice President, Chief Medical Officer and Head of ...